Advances in the Diagnosis and Management of Patients with Non-Tuberculin Mycobacterial Lung Disease: The Role of Amikacin-Based Inhalation Therapeutics

Program Dates: September 30th, 2022 - September 29th, 2023
Credits: 0.75 AMA PRA Category 1 Credits™

Advances in the Diagnosis and Management of Patients with Non-Tuberculin Mycobacterial Lung Disease: The Role of Amikacin-Based Inhalation Therapeutics

Program Overview

This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. Anne O’Donnell, will first outline both the prevalence and pathophysiology of non-tuberculin mycobacterial lung disease (NTM-LD). Following, current clinical trial data for mycobacterium avium complex (MAC) will be reviewed and clinical relevance debated, including a conversation of toxicities and challenges for clinicians. Dr. O’Donnell will conclude with a case-based approach to applying recent information regarding the treatment and management of NTM-LD in clinical practice.

Target Audience

Pulmonologists and other healthcare professionals who care for patients with NTM-LD


I. Scientific Review on NTM-LD – Strategies for the Early and Accurate Diagnosis

II. Clinical Trial Review of Amikacin-Based Inhalation Therapeutics for the Treatment of NTM-LD

III. The Important Role of the Interprofessional Team to Improve Diagnostics, Patient Education, Shared Decision Making, and Adherence to Treatment

Learning Objectives

  1. Review NTM-LD pathophysiology, associated patient risk factors/signs/symptoms, underlying conditions (E.g. bronchiectasis), and approaches to early and accurate diagnosis
  2. Analyze clinical trial data on amikacin-based inhalation therapeutics for the treatment of NTM-LD
  3. Engage the interprofessional team to be aware of diagnostic symptoms, as well as enhance patient education, shared decision making, and adherence to treatment


Sidney S. Braman, MD
Professor of Medicine, Emeritus
Icahn School of Medicine at Mount Sinai
New York, NY



Anne E. , MD
Professor of Medicine
Division Chief, Pulmonary Medicine, Critical Care, and Sleep Medicine
Georgetown University School of Medicine
Washington, DC


Disclosures of Relevant Financial Relationships

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Sidney S. Braman, MD Nothing to disclose
Anne E. O’Donnell, MD Consultant/Advisor: Boehringer Ingelheim; Electromed, Inc.; Insmed; Paratek Pharma; ZAMBON COMPANY S.P.A.

Grant/Research Support: Boehringer Ingelheim; Insmed; Paratek Pharma; RedHill Biopharma Ltd.; ZAMBON COMPANY S.P.A.

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits TM.

Clinicians should only claim credit commensurate with the extent of their participation.

Financial Support

This activity has been supported by an independent educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Insmed do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].


Provided by: AcademicCME-web